Back to Journals » Neuropsychiatric Disease and Treatment » Volume 11

Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses

Authors Bortolato B, Miskowiak K, Köhler C, Vieta E, Carvalho A

Received 20 August 2015

Accepted for publication 13 October 2015

Published 17 December 2015 Volume 2015:11 Pages 3111—3125

DOI https://doi.org/10.2147/NDT.S76700

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Roumen Kirov

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Beatrice Bortolato,1 Kamilla W Miskowiak,2 Cristiano A Köhler,3 Eduard Vieta,4 André F Carvalho3

1Department of Mental Health, ULSS 10 “Veneto Orientale”, Venice, Italy; 2Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 3Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil; 4Bipolar Disorders Program, Institute of Neuroscience, Hospital Clínic Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Catalonia, Spain

Abstract:
Cognitive impairment is a core feature of schizophrenia (SZ) and bipolar disorder (BD). A neurocognitive profile characterized by widespread cognitive deficits across multiple domains in the context of substantial intellectual impairment, which appears to antedate illness onset, is a replicated finding in SZ. There is no specific neuropsychological signature that can facilitate the diagnostic differentiation of SZ and BD, notwithstanding, neuropsychological deficits appear more severe in SZ. The literature in this field has provided contradictory results due to methodological differences across studies. Meta-analytic techniques may offer an opportunity to synthesize findings and to control for potential sources of heterogeneity. Here, we performed a systematic review of meta-analyses of neuropsychological findings in SZ and BD. While there is no conclusive evidence for progressive cognitive deterioration in either SZ or BD, some findings point to more severe cognitive deficits in patients with early illness onset across both disorders. A compromised pattern of cognitive functioning in individuals at familiar and/or clinical risk to psychosis as well as in first-degree relatives of BD patients suggests that early neurodevelopmental factors may play a role in the emergence of cognitive deficits in both disorders. Premorbid intellectual impairment in SZ and at least in a subgroup of patients with BD may be related to a shared genetically determined influence on neurodevelopment.

Keywords: schizophrenia, bipolar disorder, psychosis, neuropsychological tests, cognition, meta-analysis, psychiatry

Introduction

Cognitive impairment is a common feature in schizophrenia (SZ) and a determinant of poor functional outcome. A neurocognitive profile characterized by cognitive deficits across multiple domains in the context of a general intellectual impairment has been consistently reported in the SZ literature.1,2 More recently, the evaluation of neuropsychological profile in young individuals at clinical high risk (CHR) for psychosis and in individuals with familiar high risk (FHR) has become a focus for research designed to explore putative neurocognitive predictors of transition to full-blown psychosis.3,4 In youth, prodromic conditions associated with increased risk of psychosis are operationally defined by the presence of either an attenuated psychosis syndrome or brief limited intermittent psychotic symptoms or genetic/familial risk to psychosis associated with functional decline.5 Evidence suggests that cognitive dysfunction occurs in individuals with FHR to psychosis and in young populations at ultra-high-risk (UHR) to psychosis.6 In addition, reduced premorbid intelligence quotient (~0.5 standard deviations [SDs] below average)7 during childhood has been associated with a higher risk to develop SZ.1,8

For bipolar disorder (BD), substantial albeit less severe cognitive dysfunction has been consistently shown across several domains in affected individuals even during the first episode as well as in unaffected relatives.9,10 In contrast to SZ, there is little evidence of premorbid global intellectual impairment in BD.11 In keeping with this, it has been posited that neurodevelopmental deficits may occur in SZ but not necessarily in BD. However, some experts have argued that neurodevelopmental factors may also contribute to cognitive deficits during the premorbid phase of at least a subgroup of individuals who would subsequently develop full-blown BD.12 Similarly, prodromic features in BD have been consistently described in the literature, notwithstanding the specificity and predictive validity of a putative bipolar prodrome remain unclear.1315

Some methodological discrepancies may limit the comparability of studies of cognitive dysfunction in BD and/or SZ, including differences in study design (eg, different neuropsychological tests across investigations and practice effects) and sample characteristics (eg, illness duration, age of illness onset, clinical state, treatment status, as well as the inclusion of appropriately age- and sex-matched healthy individuals as controls). Furthermore, a nonunivocal definition of neuropsychological domains based on the grouping of specific tasks is a further source of inconsistency across studies. Meta-analytic techniques allow the incorporation of data across different studies, and may aid in the identification of potential sources of heterogeneity across studies, albeit being influenced by inherent limitations of included studies.

Thus, we performed a systematic review of meta-analyses of neuropsychological studies performed in samples with established diagnoses of BD and/or SZ, as well as in young individuals with a first manic or psychotic episode, unaffected first-degree relatives (FDRs) of patients with BD/SZ, and in individuals at FHR and/or CHR for either BD or SZ.

Methods

The PubMed database was searched from inception to August 10, 2015 with combinations of the following search terms: (“Cognitive deficits” OR “cognitive dysfunction” OR “Executive Function” OR “Attention” OR “Memory” OR “neuropsycho*”) AND (“Schizophrenia” OR “Psychotic Disorder” OR “Bipolar Disorder” OR “familiar-high risk” OR “clinical-high risk”) AND “Meta-Analysis”. Reference lists of included articles were hand searched to augment this search strategy.

Meta-analyses published in English were included if the primary focus was on neurocognitive performance in the following populations: i) participants with a diagnosis of either SZ or BD (established through a structured diagnostic interview according to either the Diagnostic and Statistical Manual of Mental Disorders or the International Classification of Diseases criteria); ii) individuals on their first-episode manic or psychotic episode; iii) unaffected relatives; and iv) young individuals at-risk to develop BD or SZ. CHR herein refers to a prodromal state associated with a higher risk of developing psychosis within the first 3 years of presentation, while FHR is defined by the presence of a parent of sibling with SZ or at least two relatives with SZ.3,4

This search strategy provided 717 references that were screened for potential inclusion on the basis of the title and abstract. We decided to specifically focus on quantitative analyses of neurocognitive performance and/or global cognitive functioning, while meta-analyses on social cognition were not considered for this review. A total of 58 meta-analyses met the inclusion criteria: 14 on cognitive dysfunction in BD and in FDRs (Table 1 for single references), 24 on SZ (Table 2), seven meta-analyses of studies comparing cognitive performance between individuals with BD and SZ, and 13 meta-analyses of studies on individuals at CHR or FHR to psychosis. Figure 1 provides a description of the search terms and included studies.

Table 1 Meta-analytic evidence of neurocognitive impairment in BD and in FDRs listed in chronological order of publication
Abbreviations: AP, affective psychosis; BD, bipolar disorder; ES, effect size; FDRs, first-degree relatives; FEBD, first-episode BD; FES, first-episode schizophrenia; HC, healthy controls; IQ, intelligence quotient; SZ, schizophrenia; TMT-B, trail making test B; WCST, Wisconsin Card Sorting Test.

Table 2 Meta-analytic evidence of neurocognitive impairment in SZ listed in chronological order of publication
Note: See the text for meta-analyses of studies focusing on cognitive performance in individuals at FHR and CHR to psychosis.
Abbreviations: BD, bipolar disorder; CHR, clinical high risk; ES, effect size; FHR, familiar high risk; FES, first-episode schizophrenia; HC, healthy controls; HCT, Halstead Category Test; IQ, intelligence quotient; SMD, standardized mean difference; SZ, schizophrenia; TMT-B, trail making test B; WCST, Wisconsin Card Sorting Test.

Figure 1 Flow-chart describing the search strategy for the inclusion of eligible meta-analyses.
Abbreviations: BD, bipolar disorder; SZ, schizophrenia.

We considered standardized effect sizes (ESs) <0.5 as small, ≥0.5 and <0.8 medium, and ≥0.8 large.16

Cognitive dysfunction in BD

Cognitive impairment in individuals with BD

Notwithstanding a certain degree of inconsistency in the results of separate meta-analysis, BD has been consistently associated with cognitive dysfunction across a broad range of cognitive domains (Table 1). Neurocognitive deficits persist in periods of euthymia and thus have been considered trait-related markers of the disorder. For example, medium-to-large ES differences in neurocognitive performance have been reported between euthymic patients and controls in the domains of attention, processing speed, episodic memory, and executive functions.17 A separate meta-analysis indicated that individuals with BD during euthymia exhibit neuropsychological impairment of medium-to-large ES, notably in measures of verbal learning and memory.18 During manic/mixed states, additional decrements on measures of verbal learning were also observed, while patients in a depressed state exhibited greater impairment in measures of phonemic fluency.18 Subsequently, widespread medium-to-large ES cognitive impairment across several domains in BD compared to healthy controls was reported,19 similar to the observed nonspecific cognitive deficits in SZ but less pronounced.20 More recently, an individual patient meta-analysis of 31 datasets assessing measures of four specific tests (Verbal learning tests, Trail Making Test, Digit Span, and Wisconsin Card Sorting Test) indicated deficits in euthymic individuals with BD of small-to-medium ES after controlling for age, intelligence quotient, sex, and residual mood symptoms.21 Young adults after a first episode of BD exhibit a widespread cognitive impairment,10 the level of which appears comparable to that reported for individuals with recurrent episodes.21 In comparison to previous meta-analyses on euthymic BD patients with recurrent episodes reporting a large degree of impairment,17,18,20,22,23 this meta-analysis on adults with a first episode of BD indicates a more modest level of mood-state-independent cognitive dysfunction21 which is consistent with a staging model for the disease based on neuroprogression24 characterized by progressive impairment over time in the majority of BD patients. In fact, greater neuropsychological dysfunction (notably deficits in verbal memory) has been associated with the number of previous manic episodes and hospitalizations as well as with illness duration.2527 In keeping with this view, another meta-analysis indicated a negative correlation between illness duration and age with cognitive performance.20 However, other quantitative studies failed to replicate this finding, possibly because of methodological factors including those related to sample selection and inherent limitations of meta-regression techniques.22 Conversely, earlier age of onset has been associated with greater impairment in verbal memory and psychomotor speed,22 although this result was not confirmed by other meta-analyses.10

Psychotic features in BD have been associated with worse cognitive performance as compared to nonpsychotic BD in tasks of verbal memory and executive function (planning/reasoning measures), working memory and processing speed.28 Another meta-analysis of cognitive impairment in individuals with affective psychosis (AP) indicated that individuals with AP perform approximately 0.8 SD lower than HC19 in 11 of 15 studied cognitive measures, with larger ES for measures of attention, working memory, and executive function.29 The pattern of cognitive impairment in AP appears comparable to that reported for euthymic BD patients, but more pronounced. However, as a result of the inclusion in this analysis of studies with heterogeneous patient population (ie, individuals with Major Depressive Disorder and with BD), these results must be interpreted with caution. Only one meta-analysis investigated the possible differences in neurocognitive performance between individuals with BD type I and BD type II. This study indicated a relatively specific greater impairment in verbal memory of medium ES (Cohen’s d=0.52) in BD I, while no differences between these BD subgroups were observed in global cognition, attention, working memory, and executive function.30 Thus, the authors postulated that memory impairment, reflecting neuroanatomical medial temporal abnormalities, might be a specific endophenotype for type I BD, possibly resulting from neuroprogressive damages associated with manic episodes.30

Neurocognitive performance represents a moderate determinant of functional impairment and disability in BD as well as a predictor of unfavorable employment outcomes.7,31,32 This is particularly relevant considering that up to two-third of individuals with BD do not achieve functional recovery even when affective remission is evident. A meta-analysis documented a significant correlation between cognitive deficits and reduced functional abilities for all the considered cognitive domains, being largest (r=0.29) for deficits in working memory (r=0.29).33 Notably, the contribution of cognitive impairment to disability appears to be independent of symptoms, as indicated by the absence of difference in ES between studies including only euthymic patients vs studies enrolling actively symptomatic BD participants. Further evidence of the relevance of cognitive performance on psychosocial functioning is the fact that certain interventions, mainly based on ecological cognitive training, proved effective in improving functional outcome in euthymic BD patients.34

Regarding the longitudinal course of cognitive deficits, available data are scarce and inconsistent. BD has been conceptualized as a neuroprogressive illness with a subtle neurodevelopmental component preceding illness onset, followed by neurodegeneration after the first episode and progressive cognitive decline as a function of recurrences.35 The presence of a neurodevelopmental component of cognitive dysfunction in BD is supported by quantitative analyses in pediatric BD populations, showing cognitive deficits of small-to-moderate ES across different cognitive domains.36 However, the hypothesis of the association between cognitive impairment and the cumulative number of episodes,25 as a proxy of the neuroprogressive nature of BD,37 is based on cross-sectional studies and the direction of causality remains unclear. A meta-analysis evaluating available data on the longitudinal course of neurocognitive performance in BD did not document test–retest differences in ES for any of the cognitive variables studied.38 Additionally, no significant patient-control ES differences in neurocognitive performance were observed. These findings do not support the hypothesis of a progressive deterioration of cognitive abilities in BD. A previous quantitative analysis of cognitive dysfunction in euthymic late-life BD individuals further argues that deficits appear stable over time, showing similar ES differences to those reported for young adults with BD.39 In particular, half of late-life BD patients exhibited cognitive dysfunction on average between 0.6 and 0.9 SD below that of healthy controls, with a medium ES for sustained attention and category fluency and large ES for cognitive flexibility and phonemic fluency (parts of executive function). An alternative explanation is that BD represents a heterogeneous phenotype, in which different illness trajectories could lead to distinct degrees of cognitive impairment as a function of recurring episodes.40 Moreover, these findings could have been heavily influenced by the fact that longitudinal studies only assess the patients who stay on treatment and who are adherent to follow-up. Several studies indicate that the patients receiving lithium maintenance treatment do not progressively deteriorate in cognitive functioning.41,42 Furthermore, some longitudinal studies assess baseline cognitive performance shortly after hospital discharge or after a recent episode, which leaves little room for the detection of changes over time because patients show an already well-established significant impairment. Other several limitations of the available evidence should be considered in future prospective studies in order to elucidate the nature of cognitive dysfunction in BD, including i) a short duration of follow-up periods; ii) small sample sizes (and high attrition rates in prospective studies resulting in an unintended selection of the less deteriorated patients over time); iii) the absence of a healthy control group; and iv) the lack of a proper control for affective symptomatology across different follow-up assessments.

Cognitive impairment in first-degree relatives of BD patients

The presence of cognitive impairment not only in BD patients but also in FDRs led to the hypothesis that specific aspects of cognitive dysfunction may be trait markers of the disorder and potential candidate endophenotypes. For instance, while large ES were observed for euthymic individuals with BD for deficits in verbal memory and in executive functions (eg, executive control, fluency), FDRs exhibited deficits of smaller magnitude but significantly different compared to healthy controls in verbal memory and executive functions.23 A subsequent meta-analysis suggested that deficits in response inhibition could be a potential endophenotype for BD and a potential marker of ventral prefrontal dysfunction in BD.22 In this quantitative study, deficits of small-to-medium ES were reported for set shifting and verbal memory as well, and have been postulated to represent potential generic markers of psychosis, being candidate endophenotypes for both BD and SZ. Moreover, separate components of sustained attention have been postulated to have a role as potential endophenotypes for BD and SZ (ie, target detection impairment [false negatives] vs false alarms [false positives]).43

Cognitive dysfunction in schizophrenia

Cognitive impairment in individuals with SZ

The first large-scale meta-analysis of cognitive impairment in SZ, including more than 200 studies performed between 1980 and 1997, documented an overall mean impairment of 0.9 SD relative to community control groups.46 Subsequently, updated meta-analyses confirmed such nonspecific neurocognitive impairment encompassing across several domains in SZ, with largest ES in episodic memory and processing speed47,48 (Table 2). Consistent with this, several meta-analyses documented deficits of large ES in different cognitive areas including intellectual function, learning and memory, attention, working memory, language and executive function, despite great clinical and methodological heterogeneity across included studies.4953 More recently, the robustness of these findings has been confirmed in a meta-analysis documenting significant nonspecific cognitive deficits (grand mean ES g=−1.03), with most pronounced impairment in processing speed (g=−1.25) and episodic memory (g=−1.23).54 Processing speed has been identified as a central feature of cognitive decline in SZ, with largest ES for coding tasks and category fluency.55,56 With regard to deficits in episodic memory, a meta-analysis of functional neuroimaging studies documented a prominent prefrontal dysfunction in individuals with SZ during encoding and retrieval tasks compared to healthy volunteers, supporting the role of abnormal cognitive control processes in contributing to episodic memory deficits.57

When considering only elderly SZ patient populations (ie, aged >65 years), quantitative analysis of cross-sectional and longitudinal studies provided evidence of large ES deficits in a broad range of neuropsychological domains including processing speed, language, memory, and executive functions.58 As cognitive impairment remained stable over a 6-year period in this study,58 these results do not support a neurodegenerative or neuroprogressive nature of SZ.59

In keeping with this, meta-analyses of longitudinal studies on neurocognitive performance in SZ have provided no clear evidence for a progressive cognitive decline and indicated the possibility of small-to-moderate improvements in several domains after illness onset,60,61 with largest ES estimates observed in tests of memory and attention as well as in tests of cognitive flexibility.2 However, the lack of a control group in most studies that have investigated neurocognitive changes in SZ, as well as the short median follow-up period, does not allow us to differentiate whether cognitive changes in SZ represent true improvements or nonspecific effects of practice-related learning.62 Furthermore, another meta-analysis of longitudinal population-based studies documented decrements of moderate ES (d=0.43) in premorbid IQ among individuals who later converted to full-blown SZ, with a positive association between greater premorbid IQ decrements and earlier onset of illness.63 Additional evidence indicates a decline in intellectual functions before or around illness onset, associated with a relative lack of gain in global cognitive abilities in longitudinal assessments after illness onset (defined by medium-sized deficits in IQ changes in patients with SZ),1 in accordance with findings in a previous meta-analysis.8 Moderately reduced IQ appears evident even in early to mid-adolescence and seem to precede the prodromal phase of illness.64 Convergent evidence supports the hypothesis that generalized intellectual deficits contribute to executive dysfunction in SZ, despite the use of heterogeneous neuropsychological tools in the evaluation of this domain. For instance, large ES deficits in measures of cognitive flexibility65 as well as of verbal fluency66,67 have been posited to reflect a generalized intellectual impairment rather that specific difficulties in executive control processes. On the other hand, global executive functioning does not refer to a unitary cognitive dimension, but represents a set of basic low-level cognitive subcomponents (eg, shifting, updating, inhibition of dominant responses, and planning) and it has been more recently postulated that global executive dysfunction may at least in part be driven by specific deficits in cognitive inhibitory processes.68 A meta-analysis of functional neuroimaging studies on individuals with SZ during executive tasks (eg, delayed match to sample, N-back, and Stroop test) indicated that patients’ executive deficits are accompanied by hypo-activity in the dorsolateral prefrontal cortex and rostral–dorsal cingulate cortex as well as compensatory hyper-activity of other prefrontal regions.69

Chronicity, severity of symptoms, comorbidity, as well as medication status and dosage act as possible moderators of cognitive performance in SZ populations. Negative symptoms and disorganization appear to be correlated with deficits in executive functions as well as with impaired intellectual functioning in SZ.70,71 The presence of obsessive-compulsive symptoms and comorbid obsessive-compulsive disorder in the context of SZ may be associated with greater impairment in abstract thinking and in functional capacity.72 With regard to the age of illness onset, there is some evidence that early onset is associated with greater severity of cognitive impairment as compared to individuals with an adult-onset of SZ, with larger deficits in IQ, executive functioning, psychomotor speed, and verbal memory.73 However, these results should be interpreted with caution considering that the definition of early vs late age of onset is arbitrary and the inclusion of studies involving not only SZ patients but also individuals with schizoaffective disorder, schizophreniform, or delusional disorder.

With regard to the effect of medications, modest improvements in overall cognitive functions as well as specific improvements in learning and processing speed have been associated with the use of atypical as compared to typical antipsychotics,74,75 while high dosage of antipsychotic medications emerged among the factors exerting a negative influence on processing speed.56 Different antipsychotic drugs differ in long-term effects on overall cognition and on specific cognitive domains. Quetiapine and olanzapine may be associated with more positive effects in terms of neurocognition, followed in order by risperidone, ziprasidone, amisulpride, and haloperidol.76

Meta-analyses of studies specifically focusing on first-episode SZ patients documented widespread neurocognitive deficits as compared to healthy controls of medium-to-large ES.77 The severity of deficits in this population approached that of adults with chronic illness, being greater in immediate verbal memory and processing speed. Individuals with first-episode SZ also exhibited a substantial intellectual impairment, the degree of which was comparable to that showed in more advanced phases of illness, which supports the notion that cognitive deficits in SZ are to a large extent neurodevelopmental. A subsequent meta-analysis of studies comparing the neurocognitive profile of drug-naïve SZ patients at first episode with that of controls corroborate these results, demonstrating a similar ES impairment in verbal and visual memory, executive functions, and attention.78 It is noteworthy that the ES were comparable in these two meta-analyses despite the use of disparate neuropsychological tools.77,78 Importantly, the magnitude of these deficits is in accordance with the findings in meta-analyses of studies involving SZ patients receiving antipsychotic medications and with multiple illness episodes.32,54 These data suggest that the degree of cognitive impairment is at least partially independent of medication status.

The inadequate effect of conventional antipsychotics on cognitive dysfunction has led to an active search for pro-cognitive treatments for SZ.79 A meta-analysis of double-blind, placebo-controlled studies investigating the potential cognitive-enhancing properties of adjunctive medications targeted at cholinergic, glutamatergic, or serotonergic receptor classes, documented small improvements in verbal learning and memory (d=0.23), while the cholinergic agonist donepezil exerted a moderate effect (d=0.58) on spatial learning and memory.80 These data are particularly relevant since neurocognitive functions are critical determinants of functional outcome in SZ.81 Neurocognitive measures of crystallized verbal ability, working memory, processing speed, as well as executive function appear to be associated with objective measures of quality of life with small-to-moderate ES differences.82 Furthermore, intellectual abilities along with preserved memory and executive functions are among the determinants of self-appraisal mechanisms required for developing clinical and cognitive insight in SZ.83,84

Cognitive impairment in individuals with familiar risk and CHR to psychosis

The presence of substantial cognitive impairment also in FDRs of individuals with SZ has provided evidence supporting a role of certain cognitive deficits as candidate endophenotypes for SZ. Meta-analyses of studies on nonaffected adult relatives of SZ patients indicated the presence of medium ES differences as compared to controls in the domains of declarative and verbal memory and executive functions, while smaller ES differences were observed for attention.43,8890 Consistently, subsequent analyses of cognitive performance in adult relatives of SZ patients confirmed prior findings of moderate ES deficits in tasks of working memory, sustained attention, as well as set-shifting and response inhibition, supporting a model of neurocognitive impairment defined by a deficit in demanding executive control.91,92 Recently, there has been growing emphasis on the examination of cognitive performance in younger relatives and in individuals with familiar history of SZ (FHR) or at CHR to psychosis.93 Individuals with familiar risk (FHR) of psychosis aged <30 years exhibit cognitive deficits with moderate ES differences as compared to controls, with largest ES on estimates of full-scale IQ (d=−0.77), followed by vocabulary (d=−0.749) and single word reading test (d=−0.698), which are often used as IQ estimates.94 In line with previous meta-analyses,91 more modest ES differences were observed for measures of declarative memory, sustained attention, and working memory.94 Data from a meta-analysis of studies comparing the cognitive performance of CHR individuals (n=1,188) with that of HC (n=1,029) indicated the presence in the CHR population of small-to-medium ES reduction in general intelligence as well as across several domains including verbal fluency, executive functions, verbal and visual memory, attention, and working memory.95 In this study, more pronounced baseline deficits in general intelligence, verbal fluency, verbal and visual memory, as well as working memory predicted increased risk of transition to psychosis within 19 months from the first assessment. Consistently, another quantitative analysis that compared neurocognitive functioning among 583 CHR subjects between psychosis converters and nonconverters documented a worse cognitive profile in psychosis converters with small-to-medium ES differences in working memory (ES=−0.29) and visual learning (ES=−0.40).3

Small-to-medium ES (−0.26<d<−0.67) cognitive deficits in subjects at clinical risk to develop psychosis across various neurocognitive domains appear consistent findings across separate meta-analyses.96 In a recent quantitative analysis individuals with clinical risk to develop psychosis exhibited deficits with an intermediate degree of severity between HC and SZ patients and comparable to the level of impairment in individuals with a “genetic” familiar risk.96 Moreover, the degree of cognitive dysfunction was more pronounced among CHR who were also at familiar risk. Transition to psychosis was associated with additional cognitive impairment, characterized by deficits of medium/large ES (−0.35<d<−0.84) across several domains.96

Subsequently, a meta-analysis synthesized studies comparing the cognitive profile of FHR individuals (defined by the presence of a parent or sibling with SZ or at least two relatives) with that of UHR individuals and young healthy controls (aged <30 years).4 The UHR paradigm represents a CHR model targeting the identification of psychotic features in the prodromal period and is defined by the presence of one or more of three psychosis risk syndromes, including i) recent onset or worsening of attenuated positive symptoms (APS); ii) recent onset of significant psychotic features that do not fulfill the inclusion criteria for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) psychotic disorder (brief limited intermittent psychotic syndrome); and iii) genetic/familial risk to psychosis associated with functional decline syndrome. Both risk paradigms were associated with widespread cognitive deficits of moderate ES across neurocognitive domains, with greater severity in the case of the occurrence of genetic risk and attenuated symptoms. Individuals with familiar genetic risk exhibited more pronounced decrements in premorbid general intelligence as compared to individuals with clinical risk to psychosis. Moreover, more severe baseline cognitive deficits predicted increased risk of transition to psychosis in the UHR paradigm.

Quantitative analysis of prospective studies evaluating the course of neurocognitive profile over a period of 5 years in individuals with first-episode psychosis (n=905) and in UHR individuals (n=560) as compared to healthy controls (n=405) did not provide evidence of a significant cognitive decline over time,6 in accordance with previous meta-analyses.2,58 These data provide support to a neurodevelopmental model characterized by the presence of substantial cognitive impairment preceding the prodromic phases of psychosis and not associated with a significant decline during longitudinal assessments. On the contrary, improvements of comparable magnitude in global cognition were observed in all three groups. Substantial small-to-moderate ES improvements were observed both in UHR individuals and in individuals with first episode of psychosis in verbal memory, processing speed, attention, executive functions, while large improvements in all cognitive domains were also observed in healthy controls. In individuals with first-episode psychosis, the degree of improvement in verbal memory and executive functions was significantly associated with reductions in negative symptoms. The pattern of cognitive improvement appears to reflect practice-related effects, characterized by an early improvement followed by a plateau, with most consistent improvements observed in tasks of memory and executive functions (which are more sensitive to practice effects) and more limited improvements in tasks poorly associated with learning effects (eg, verbal fluency).6

Cognitive impairment in studies comparing the neurocognitive profile in BD and SZ

Few meta-analyses have compared the neurocognitive performance of BD individuals with that of individuals with SZ. The first meta-analysis comparing these groups indicated that BD patients outperformed SZ patients in nine out of eleven cognitive measures, with largest differences in ES for verbal fluency and moderate ES also for verbal working memory, mental speed, executive control, and immediate verbal memory.44 A subsequent meta-analysis comparing the neurocognitive performance of SZ patients and individuals with AP indicated worse performance in SZ patients in 6 out of 12 cognitive domains.85 This meta-analysis therefore does not support the existence of a different neurocognitive profile for BD and SZ based on categorical distinction. Nevertheless, the differences were small and the distribution of ES showed substantial heterogeneity, driven by a higher percentage of male participants, more severe negative symptoms, and earlier illness onset in SZ samples.85 Notwithstanding, these results corroborate with another meta-analysis that showed widespread cognitive impairment in both SZ and affective disorders, with quantitative rather than qualitative differences between diagnostic groups.86 Further evidence that the nature of cognitive deficits does not distinguish BD and SZ per se is provided by a meta-analysis showing a similar degree of impairment in measures of executive dysfunction in both disorders.45

A recent meta-analysis of premorbid and postonset intellectual function in BD and SZ relative to controls indicated that SZ patients exhibit moderate premorbid reduction in intellectual function (standardized mean difference =−0.597), while there is no univocal evidence of reduced premorbid intellectual capacity in BD.11 This is consistent with meta-analytical evidence for a premorbid IQ reduction of approximately 0.5 SD in young individuals that subsequently develop SZ.8

With regard to data on the early phases of BD and SZ, one meta-analysis specifically compared the neuropsychological performance of first-episode manic BD patients to first-episode SZ patients and healthy controls.9 This confirmed the existence of widespread cognitive impairment also in first-episode mania, the severity of which was lower than in first-episode SZ individuals.9 In particular, individuals with first-episode mania exhibited a level of impairment comparable to that observed in patients with greater chronicity.11,22 These findings may be explained by indirect effects of cross-sectional illness severity. Additionally, another quantitative study comparing the neurocognitive profile of individuals with early onset SZ with that of individuals with pediatric BD confirmed the presence of deficits of mostly large ES in multiple domains in SZ and a similar profile of cognitive dysfunction in BD but characterized by lower severity, with deficits in the moderate-to-large ES range.87

Taken together, these data support the relevance of neurodevelopmental factors as possible contributory factors for neurocognitive impairment in SZ as well as at least in a subgroup of individuals with BD. Moreover, convergent evidence supports that cognitive impairment is relatively independent of chronicity and treatment exposure.

Concluding remarks

Data from the available meta-analytic literature suggest a significant overlap of impairment between the neuropsychological profiles in established BD and SZ, with differences being more quantitative than qualitative. Cognitive deficits are recognizable early in the trajectory of both disorders and are evident in individuals at their first manic or psychotic episode. A significant impairment during childhood and in the early adolescence before the onset of psychosis supports the role of neurodevelopmental factors in SZ and for at least in a subgroup of individuals with BD.12 Premorbid reduction in intellectual ability and developmental lags, consisting in a relative lack of gain in cognitive abilities before or around illness onset, has been consistently documented in SZ1,75 and has been associated with common susceptibility genes.97 On the contrary, data on premorbid intellectual functioning in BD provide equivocal results.11 Longitudinal studies investigating the trajectory of premorbid cognitive deficits in BD are scarce compared to SZ, but a review of available literature to date suggest an inverted U-shaped relationship between premorbid cognitive functioning and risk to develop BD, with both poor and “brilliant” cognitive/scholar functioning associated with increased risk to develop BD in adulthood.12 Thus, it is plausible that shared susceptibility genes in SZ and BD are associated with neurodevelopmental abnormalities, which may predict early cognitive dysfunction at least in subgroups of patients.98,99 On the other side, another subgroup of BD patients may have excellent baseline cognitive skills, which might, or might not deteriorate over time depending on the course of illness, treatment adherence, and healthy habits.100 Early deleterious effects of psychosocial stress and epigenetic modulation of genes related to increased oxidative stress and dysfunctional cellular energy metabolism play a role both in SZ and BD.101103 Thus, these shared pathophysiological pathways may contribute to similar early cognitive deficits in both illnesses.

A better understanding of the longitudinal trajectory of cognitive dysfunction as well as of predictors of transition to full-blown SZ and BD would advance our knowledge on potential early psychological and pharmacological interventions prevent cognitive deterioration and illness onset. Psychoeducation, cognitive behavioral therapy, functional remediation in BD,104 cognitive remediation in SZ,73 as well as pharmacological interventions may reduce conversion rates, but their effect on functional outcome remains unclear.105 More research into potential sources of heterogeneity is warranted to elucidate the timing and trajectory of cognitive dysfunction in BD and in SZ in order to provide more effective and individualized treatment interventions. Finally, it should be noted that both SZ and BD are heterogeneous phenotypes (ie, an established diagnosis of either SZ or BD may encompass distinct psychopathological entities with otherwise deceptively similar neurobiological underpinnings).

Disclosure

CAK is the recipient of a postdoctoral fellowship award from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; Brazil) and AFC is the recipient of a research fellowship award from the Conselho de Desenvolvimento Científico e Tecnológico (CNPq; Brazil). KWM has received support or served as a consultant for Lundbeck. EV has received grants and served as consultant, advisor, or speaker for: Alexza, Almirall, AstraZeneca, Bristol-Myers Squibb, Cephalon, Elan, Eli Lilly, Ferrer, Forest Research Institute, an Allergan affiliate, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Johnson and Johnson, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, ScheringPlough, Shire, the Spanish Ministry of Science and Innovation, the Seventh European Framework Programme, the Stanley Medical Research Institute, Sunovion, Takeda, Teva, United BioSource Corporation, and Wyeth. BB, CAK and AFC report no conflicts of interest in this work.


References

1.

Hedman AM, van Haren NE, van Baal CG, Kahn RS, Hulshoff Pol HE. IQ change over time in schizophrenia and healthy individuals: a meta-analysis. Schizophr Res. 2013;146(1–3):201–208.

2.

Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiat J Mental Sci. 2008;192(4):248–257.

3.

De Herdt A, Wampers M, Vancampfort D, et al. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis. Schizophr Res. 2013;149(1–3):48–55.

4.

Bora E, Lin A, Wood SJ, Yung AR, McGorry PD, Pantelis C. Cognitive deficits in youth with familial and clinical high risk to psychosis: a systematic review and meta-analysis. Acta Psychiatr Scand. 2014;130(1):1–15.

5.

Schultze-Lutter F, Schimmelmann BG, Ruhrmann S, Michel C. ‘A rose is a rose is a rose’, but at-risk criteria differ. Psychopathology. 2013;46(2):75–87.

6.

Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40(4):744–755.

7.

Baune BT, Li X, Beblo T. Short- and long-term relationships between neurocognitive performance and general function in bipolar disorder. J Clin Exp Neuropsychol. 2013;35(7):759–774.

8.

Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiat. 2008;165(5):579–587.

9.

Bora E, Pantelis C. Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. Schizophr Bull. 2015.

10.

Lee RS, Hermens DF, Scott J, et al. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. J Psychiatr Res. 2014;57:1–11.

11.

Trotta A, Murray RM, MacCabe JH. Do premorbid and post-onset cognitive functioning differ between schizophrenia and bipolar disorder? A systematic review and meta-analysis. Psychol Med. 2014:1–14.

12.

Bora E. Developmental trajectory of cognitive impairment in bipolar disorder: comparison with schizophrenia. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2015;25(2):158–168.

13.

Bechdolf A, Ratheesh A, Cotton SM, et al. The predictive validity of bipolar at-risk (prodromal) criteria in help-seeking adolescents and young adults: a prospective study. Bipolar Disord. 2014;16(5):493–504.

14.

Faedda GL, Serra G, Marangoni C, et al. Clinical risk factors for bipolar disorders: a systematic review of prospective studies. J Affect Disord. 2014;168:314–321.

15.

Faedda GL, Marangoni C, Serra G, et al. Precursors of bipolar disorders: a systematic literature review of prospective studies. J Clin Psychiat. 2015;76(5):614–624.

16.

Cohen J. A power primer. Psychol Bull. 1992;112(1):155–159.

17.

Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl. 2007;(434):17–26.

18.

Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009;23(5):551–562.

19.

Steinberg S, de Jong S, Mattheisen M, et al. Common variant at 16p11.2 conferring risk of psychosis. Mol Psychiat. 2014;19(1):108–114.

20.

Mann-Wrobel MC, Carreno JT, Dickinson D. Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. Bipolar Disord. 2011;13(4):334–342.

21.

Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand. 2013;128(3):149–162.

22.

Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord. 2009;113(1–2):1–20.

23.

Arts B, Jabben N, Krabbendam L, van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med. 2008;38(6):771–785.

24.

Kapczinski F, Magalhaes PV, Balanza-Martinez V, et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014;130(5):354–363.

25.

Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1–3):105–115.

26.

Martinez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiat. 2004;161(2):262–270.

27.

Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12(5):557–567.

28.

Bora E, Yucel M, Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study. J Affect Disord. 2010;127(1–3):1–9.

29.

Bora E, Yucel M, Pantelis C. Cognitive impairment in affective psychoses: a meta-analysis. Schizophr Bull. 2010;36(1):112–125.

30.

Bora E, Yucel M, Pantelis C, Berk M. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand. 2011;123(3):165–174.

31.

Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord. 2010;12(4):364–375.

32.

Tse S, Chan S, Ng KL, Yatham LN. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014;16(3):217–229.

33.

Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14(3):217–226.

34.

Torrent C, Bonnin Cdel M, Martinez-Aran A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiat. 2013;170(8):852–859.

35.

Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med. 2011;41(2):225–241.

36.

Joseph MF, Frazier TW, Youngstrom EA, Soares JC. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J Child Adolescent Psychopharmacol. 2008;18(6):595–605.

37.

Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res. 2012;46(5):561–573.

38.

Samame C, Martino DJ, Strejilevich SA. Longitudinal course of cognitive deficits in bipolar disorder: a meta-analytic study. J Affect Disord. 2014;164:130–138.

39.

Samame C, Martino DJ, Strejilevich SA. A quantitative review of neurocognition in euthymic late-life bipolar disorder. Bipolar Disord. 2013;15(6):633–644.

40.

Birmaher B, Gill MK, Axelson DA, et al. Longitudinal trajectories and associated baseline predictors in youths with bipolar spectrum disorders. Am J Psychiat. 2014;171(9):990–999.

41.

Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. Psychol Med. 2013;43(6):1187–1196.

42.

Lopez-Jaramillo C, Lopera-Vasquez J, Ospina-Duque J, et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiat. 2010;71(8):1055–1060.

43.

Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res. 2004;71(2–3):285–295.

44.

Krabbendam L, Arts B, van Os J, Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005;80(2–3):137–149.

45.

Wang K, Song LL, Cheung EF, Lui SS, Shum DH, Chan RC. Bipolar disorder and schizophrenia share a similar deficit in semantic inhibition: a meta-analysis based on Hayling Sentence Completion Test performance. Prog Neuro-psychopharmacol Biol Psychiat. 2013;46:153–160.

46.

Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426–445.

47.

Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiat. 2007;64(5):532–542.

48.

Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychol Bull. 2007;133(5):833–858.

49.

Johnson-Selfridge M, Zalewski C. Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizophr Bull. 2001;27(2):305–316.

50.

Pelletier M, Achim AM, Montoya A, Lal S, Lepage M. Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis. Schizophr Res. 2005;74(2–3):233–252.

51.

Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychol Med. 2009;39(6):889–905.

52.

Wang Y, Cui J, Chan RC, et al. Meta-analysis of prospective memory in schizophrenia: nature, extent, and correlates. Schizophr Res. 2009;114(1–3):64–70.

53.

Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiat. 2012;12:64.

54.

Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150(1):42–50.

55.

Bokat CE, Goldberg TE. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res. 2003;64(1):73–78.

56.

Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiat. 2010;167(7):828–835.

57.

Ragland JD, Laird AR, Ranganath C, Blumenfeld RS, Gonzales SM, Glahn DC. Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiat. 2009;166(8):863–874.

58.

Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull. 2011;37(6):1318–1326.

59.

Davis J, Moylan S, Harvey BH, Maes M, Berk M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Austr N Z J Psychiat. 2014;48(6):512–529.

60.

Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2):201–222.

61.

Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiat. 2001;158(2):176–184.

62.

Balanza-Martinez V, Cuesta MJ, Arango C, Crespo-Facorro B, Tabares-Seisdedos R. Longitudinal course of cognition in schizophrenia. Br J Psychiatry. 2009;195(1):84; author reply 85.

63.

Khandaker GM, Barnett JH, White IR, Jones PB. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophr Res. 2011;132(2–3):220–227.

64.

Dickson H, Laurens KR, Cullen AE, Hodgins S. Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia. Psychol Med. 2012;42(4):743–755.

65.

Laws KR. A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: general intellectual deficit in disguise? Cogn Neuropsychiat. 1999;4(1):1–30; discussion 31–35.

66.

Henry JD, Crawford JR. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. Cogn Neuropsychiat. 2005;10(1):1–33.

67.

Doughty OJ, Done DJ. Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies. Cogn Neuropsychiat. 2009;14(6):473–509.

68.

Westerhausen R, Kompus K, Hugdahl K. Impaired cognitive inhibition in schizophrenia: a meta-analysis of the Stroop interference effect. Schizophr Res. 2011;133(1–3):172–181.

69.

Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiat. 2009;66(8):811–822.

70.

Dibben CR, Rice C, Laws K, McKenna PJ. Is executive impairment associated with schizophrenic syndromes? A meta-analysis. Psychol Med. 2009;39(3):381–392.

71.

Nieuwenstein MR, Aleman A, de Haan EH. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res. 2001;35(2):119–125.

72.

Cunill R, Huerta-Ramos E, Castells X. The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis. Psychiat Res. 2013;210(1):21–28.

73.

Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2009;195(4):286–293.

74.

Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1–3):211–224.

75.

Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol Off Sci J Colleg Int Neuropsychopharmacolog. 2005;8(3):457–472.

76.

Desamericq G, Schurhoff F, Meary A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127–134.

77.

Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23(3):315–336.

78.

Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr Res. 2014;158(1–3):156–162.

79.

Martinez-Aran A, Vieta E. Cognition as a target in schizophrenia, bipolar disorder and depression. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2015;25(2):151–157.

80.

Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013;203(3):172–178.

81.

Green MF, Llerena K, Kern RS. The “right stuff” revisited: what have we learned about the determinants of daily functioning in schizophrenia? Schizophr Bull. 2015;41(4)781–785.

82.

Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38(2):304–315.

83.

Nair A, Palmer EC, Aleman A, David AS. Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis. Schizophr Res. 2014;152(1):191–200.

84.

Aleman A, Agrawal N, Morgan KD, David AS. Insight in psychosis and neuropsychological function: meta-analysis. Br J Psychiatry. 2006;189:204–212.

85.

Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry. 2009;195(6):475–482.

86.

Stefanopoulou E, Manoharan A, Landau S, Geddes JR, Goodwin G, Frangou S. Cognitive functioning in patients with affective disorders and schizophrenia: a meta-analysis. Int Rev Psychiat (Abingdon, Engl). 2009;21(4):336–356.

87.

Nieto RG, Castellanos FX. A meta-analysis of neuropsychological functioning in patients with early onset schizophrenia and pediatric bipolar disorder. J Clinical Child Adolescent Psychol. 2011;40(2):266–280.

88.

Trandafir A, Meary A, Schurhoff F, Leboyer M, Szoke A. Memory tests in first-degree adult relatives of schizophrenic patients: a meta-analysis. Schizophr Res. 2006;81(2–3):217–226.

89.

Whyte MC, McIntosh AM, Johnstone EC, Lawrie SM. Declarative memory in unaffected adult relatives of patients with schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2005;78(1):13–26.

90.

Szoke A, Schurhoff F, Mathieu F, Meary A, Ionescu S, Leboyer M. Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychol Med. 2005;35(6):771–782.

91.

Snitz BE, Macdonald III AW, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32(1):179–194.

92.

Jameson KG, Nasrallah HA, Northern TG, Welge JA. Executive function impairment in first-degree relatives of persons with schizophrenia: a meta-analysis of controlled studies. Asian J Psychiat. 2011;4(2):96–99.

93.

Hoff AL, Svetina C, Maurizio AM, Crow TJ, Spokes K, DeLisi LE. Familial cognitive deficits in schizophrenia. Am J Med Genet B, Neuropsychiatr Gen. 2005;133b(1):43–49.

94.

Agnew-Blais J, Seidman LJ. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: a quantitative and qualitative review. Cogn Neuropsychiat. 2013;18(1–2):44–82.

95.

Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiat. 2012;69(6):562–571.

96.

Giuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ. Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharmaceut Des. 2012;18(4):399–415.

97.

Lencz T, Knowles E, Davies G, et al. Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: a report from the Cognitive Genomics consorTium (COGENT). Mol Psychiat. 2014;19(2):168–174.

98.

Gatt JM, Burton KL, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res. 2015;60:1–13.

99.

Sleiman P, Wang D, Glessner J, et al. GWAS meta analysis identifies TSNARE1 as a novel schizophrenia/bipolar susceptibility locus. Sci Rep. 2013;3:3075.

100.

Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand. 2014;129(5):323–327.

101.

Nordholm D, Krogh J, Mondelli V, Dazzan P, Pariante C, Nordentoft M. Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis. Psychoneuroendocrinology. 2013;38(11):2394–2404.

102.

Andreazza AC, Kauer-Sant’anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111(2–3):135–144.

103.

Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010;53(1):112–124.

104.

Bonnin CM, Torrent C, Vieta E, Martinez-Aran A. Restoring functioning in bipolar disorder: functional remediation. Harvard Rev Psychiat. 2014;22(6):326–330.

105.

Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiat J Assoc Eur Psychiatr. 2015;30(3):388–404.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]